この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。
ビジネス · 1997/11/201 分で読めます
Urologix, Inc.; Premarket Approval of the T3Register Targeted Transurethral Thermoablation System: Model 4000
ローカル自動翻訳 · 情報源の原言語
概要
The Food and Drug Administration (FDA) is announcing its approval of the application by Urologix, Inc., Minneapolis, MN, for premarket approval, under the Federal Food, Drug, and Cosmetic Act (the act), of the T3 Targeted Transurethral Thermoablation System: Model 4000. FDA's Center for Devices and Radiological Health (CDRH) notified the applicant, by letter of August 22, 1997, of the approval of the application.
情報源の原言語: Federal Register — Food and Drug Administration原文の発表を開く →